Literature DB >> 32959046

CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.

Marie Le Cann1, Françoise Bouhour2, Karine Viala3, Laurence Simon1, Céline Tard4, Cédric Rossi5, Guillaume Morel6, Emmeline Lagrange7, Laurent Magy8, Alain Créange9,10, Maud Michaud11, Jérôme Franques12, Andoni Echaniz-Laguna13,14,15, Jean-Christophe Antoine16, Marine Baron1, Bertrand Arnulf17, Angela Puma18, Emilien Delmont19, Thierry Maisonobe3, Véronique Leblond1, Damien Roos-Weil1.   

Abstract

CANOMAD (chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M [IgM] paraprotein, cold agglutinins, and disialosyl antibodies) is a rare syndrome characterized by chronic neuropathy with sensory ataxia, ocular, and/or bulbar motor weakness in the presence of a monoclonal IgM reacting against gangliosides containing disialosyl epitopes. Data regarding associated hematologic malignancies and effective therapies in CANOMAD are scarce. We conducted a French multicenter retrospective study that included 45 patients with serum IgM antibodies reacting against disialosyl epitopes in the context of evocating neurologic symptoms. The main clinical features were sensitive symptoms (ataxia, paresthesia, hypoesthesia; n = 45, 100%), motor weakness (n = 18, 40%), ophthalmoplegia (n = 20, 45%), and bulbar symptoms (n = 6, 13%). Forty-five percent of the cohort had moderate to severe disability (modified Rankin score, 3-5). Cold agglutinins were identified in 15 (34%) patients. Electrophysiologic studies showed a demyelinating or axonal pattern in, respectively, 60% and 27% of cases. All patients had serum monoclonal IgM gammopathy (median, 2.6 g/L; range, 0.1-40 g/L). Overt hematologic malignancies were diagnosed in 16 patients (36%), with the most frequent being Waldenström macroglobulinemia (n = 9, 20%). Forty-one patients (91%) required treatment of CANOMAD. Intravenous immunoglobulins (IVIg) and rituximab-based regimens were the most effective therapies with, respectively, 53% and 52% of partial or better clinical responses. Corticosteroids and immunosuppressive drugs were largely ineffective. Although more studies are warranted to better define the optimal therapeutic sequence, IVIg should be proposed as the standard of care for first-line treatment and rituximab-based regimens for second-line treatment. These compiled data argue for CANOMAD to be included in neurologic monoclonal gammopathy of clinical significance.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32959046     DOI: 10.1182/blood.2020007092

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

Review 1.  Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.

Authors:  Louis-Pierre Girard; Cinnie Yentia Soekojo; Melissa Ooi; Wee Joo Chng; Sanjay de Mel
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

2.  CANOMAD unmasked by COVID-19 in a man with Waldenström's macroglobulinaemia.

Authors:  Hamish D Morrison; Jonathan Cleaver; Natasha Lander; Philippa Lowden; Kate Hale; Kanchan Sharma; James Stevens
Journal:  EJHaem       Date:  2021-08-12

Review 3.  IgM monoclonal gammopathies of clinical significance: diagnosis and management.

Authors:  Jahanzaib Khwaja; Shirley D'Sa; Monique C Minnema; Marie José Kersten; Ashutosh Wechalekar; Josephine M Vos
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

Review 4.  From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.

Authors:  Andrea Visentin; Stefano Pravato; Francesca Castellani; Marta Campagnolo; Francesco Angotzi; Chiara Adele Cavarretta; Alessandro Cellini; Valeria Ruocco; Alessandro Salvalaggio; Alessandra Tedeschi; Livio Trentin; Chiara Briani
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.